FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
LYNPARZA combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial First approval of a PARP inhibitor in combination... | June 1, 2023